Mark de Caestecker
Associate Professor of Medicine
Last active: 10/23/2018

Profile

My research is focused on the mechanisms and therapeutic manipulation of intrinsic tissue repair and regenerative mechanisms following kidney injury. The long-term goal of these studies is to develop treatments that increase effective tissue repair and thereby reduce the burden of chronic kidney disease resulting from episodes of acute kidney injury. In addition to kidney research, our lab also studies the role of BMP signaling and the effects of different hereditary BMP receptor mutations, on pulmonary vascular function in patients with hereditary pulmonary arterial hypertension.

Dr. Mark de Caestecker is a Professor in Medicine, Surgery and the Department of Cell and Developmental Biology. He graduated with a BA in Medicine and Philosophy from Peterhouse College in Cambridge in 1980, and with his medical degree from the Middlesex Hospital, University of London in 1983. He completed his internship and residency equivalent at the Middlesex Hospital in London, and the Nephrology Fellowship equivalent from Manchester Royal Infirmary. From 1990 he took a break from his clinical training to study for his PhD at the University of Manchester which he successfully defended in 1994, and then went onto work as a Welcome Trust post-doctoral fellow at the NIH under the mentorship of Anita Roberts.

In addition to his lab based research program, Dr. de Caestecker practices internal medicine and nephrology at the VA hospital in Nashville, and is heavily committed to teaching graduate and medical students. He is director of the HHMI certificate Program in Molecular medicine, the Vanderbilt Center for Kidney Disease Medical Student Summer Research Training in Nephrology and the Mouse Kidney Injury Workshop.

%MCEPASTEBIN%

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Overcoming Translational Barriers in Acute Kidney Injury: A Report from an NIDDK Workshop. Zuk A, Palevsky PM, Fried L, Harrell FE, Khan S, McKay DB, Devey L, Chawla L, de Caestecker M, Kaufman JS, Thompson BT, Agarwal A, Greene T, Okusa MD, Bonventre JV, Dember LM, Liu KD, Humphreys BD, Gossett D, Xie Y, Norton JM, Kimmel PL, Star RA (2018) Clin J Am Soc Nephrol 13(7): 1113-1123
    › Primary publication · 29523680 (PubMed) · PMC6032575 (PubMed Central)
  2. BMPR2 mutations and endothelial dysfunction in pulmonary arterial hypertension (2017 Grover Conference Series). Frump A, Prewitt A, de Caestecker MP (2018) Pulm Circ 8(2): 2045894018765840
    › Primary publication · 29521190 (PubMed) · PMC5912278 (PubMed Central)
  3. Translating Knowledge Into Therapy for Acute Kidney Injury. de Caestecker M, Harris R (2018) Semin Nephrol 38(1): 88-97
    › Primary publication · 29291764 (PubMed) · PMC5894099 (PubMed Central)
  4. Zebrafish Models of Kidney Damage and Repair. Cirio MC, de Caestecker MP, Hukriede NA (2015) Curr Pathobiol Rep 3(2): 163-170
    › Primary publication · 28690924 (PubMed) · PMC5497754 (PubMed Central)
  5. Drug Discovery to Halt the Progression of Acute Kidney Injury to Chronic Kidney Disease: A Case for Phenotypic Drug Discovery in Acute Kidney Injury. Hukriede N, Vogt A, de Caestecker M (2017) Nephron 137(4): 268-272
    › Primary publication · 28614822 (PubMed)
  6. Genotype-phenotype effects of mutations on disease severity in mouse models of pulmonary hypertension. Frump AL, Datta A, Ghose S, West J, de Caestecker MP (2016) Pulm Circ 6(4): 597-607
    › Primary publication · 28090303 (PubMed) · PMC5210048 (PubMed Central)
  7. Correction: Deletion of Fibroblast Growth Factor Receptor 2 from the Peri-Wolffian Duct Stroma Leads to Ureteric Induction Abnormalities and Vesicoureteral Reflux. Walker KA, Sims-Lucas S, Di Giovanni VE, Schaefer C, Sunseri WM, Novitskaya T, de Caestecker MP, Chen F, Bates CM (2016) PLoS One 11(11): e0167191
    › Primary publication · 27861580 (PubMed) · PMC5115857 (PubMed Central)
  8. Reply to "Bone morphogenetic protein's contribution to pulmonary artery hypertension". King T, de Caestecker M, Lowery JW (2016) Surg Neurol Int : 91
    › Primary publication · 27857855 (PubMed) · PMC5093875 (PubMed Central)
  9. Antagonism of the thromboxane-prostanoid receptor is cardioprotective against right ventricular pressure overload. West JD, Voss BM, Pavliv L, de Caestecker M, Hemnes AR, Carrier EJ (2016) Pulm Circ 6(2): 211-23
    › Primary publication · 27252848 (PubMed) · PMC4869926 (PubMed Central)
  10. Pyridoxamine reduces postinjury fibrosis and improves functional recovery after acute kidney injury. Skrypnyk NI, Voziyan P, Yang H, de Caestecker CR, Theberge MC, Drouin M, Hudson B, Harris RC, de Caestecker MP (2016) Am J Physiol Renal Physiol 311(2): F268-77
    › Primary publication · 27194713 (PubMed) · PMC5008672 (PubMed Central)
  11. Bridging translation for acute kidney injury with better preclinical modeling of human disease. Skrypnyk NI, Siskind LJ, Faubel S, de Caestecker MP (2016) Am J Physiol Renal Physiol 310(10): F972-84
    › Primary publication · 26962107 (PubMed) · PMC4889323 (PubMed Central)
  12. Delayed treatment with PTBA analogs reduces postinjury renal fibrosis after kidney injury. Skrypnyk NI, Sanker S, Skvarca LB, Novitskaya T, Woods C, Chiba T, Patel K, Goldberg ND, McDermott L, Vinson PN, Calcutt MW, Huryn DM, Vernetti LA, Vogt A, Hukriede NA, de Caestecker MP (2016) Am J Physiol Renal Physiol 310(8): F705-F716
    › Primary publication · 26661656 (PubMed) · PMC4835925 (PubMed Central)
  13. Bridging Translation by Improving Preclinical Study Design in AKI. de Caestecker M, Humphreys BD, Liu KD, Fissell WH, Cerda J, Nolin TD, Askenazi D, Mour G, Harrell FE, Pullen N, Okusa MD, Faubel S, ASN AKI Advisory Group (2015) J Am Soc Nephrol 26(12): 2905-16
    › Primary publication · 26538634 (PubMed) · PMC4657852 (PubMed Central)
  14. Kidney Regeneration: Lessons from Development. Chiba T, Hukriede N, de Caestecker MP (2015) Curr Pathobiol Rep 3(1): 67-79
    › Primary publication · 26120499 (PubMed) · PMC4477536 (PubMed Central)
  15. Retinoic Acid Signaling Coordinates Macrophage-Dependent Injury and Repair after AKI. Chiba T, Skrypnyk NI, Skvarca LB, Penchev R, Zhang KX, Rochon ER, Fall JL, Paueksakon P, Yang H, Alford CE, Roman BL, Zhang MZ, Harris R, Hukriede NA, de Caestecker MP (2016) J Am Soc Nephrol 27(2): 495-508
    › Primary publication · 26109319 (PubMed) · PMC4731115 (PubMed Central)
  16. SIX2 Effects on Wilms Tumor Biology. Pierce J, Murphy AJ, Panzer A, de Caestecker C, Ayers GD, Neblett D, Saito-Diaz K, de Caestecker M, Lovvorn HN (2014) Transl Oncol 7(6): 800-11
    › Primary publication · 25500091 (PubMed) · PMC4311027 (PubMed Central)
  17. Heterozygous null bone morphogenetic protein receptor type 2 mutations promote SRC kinase-dependent caveolar trafficking defects and endothelial dysfunction in pulmonary arterial hypertension. Prewitt AR, Ghose S, Frump AL, Datta A, Austin ED, Kenworthy AK, de Caestecker MP (2015) J Biol Chem 290(2): 960-71
    › Primary publication · 25411245 (PubMed) · PMC4294523 (PubMed Central)
  18. CITED1 confers stemness to Wilms tumor and enhances tumorigenic responses when enriched in the nucleus. Murphy AJ, Pierce J, de Caestecker C, Ayers GD, Zhao A, Krebs JR, Saito-Diaz VK, Lee E, Perantoni AO, de Caestecker MP, Lovvorn HN (2014) Oncotarget 5(2): 386-402
    › Primary publication · 24481423 (PubMed) · PMC3964215 (PubMed Central)
  19. A PTBA small molecule enhances recovery and reduces postinjury fibrosis after aristolochic acid-induced kidney injury. Novitskaya T, McDermott L, Zhang KX, Chiba T, Paueksakon P, Hukriede NA, de Caestecker MP (2014) Am J Physiol Renal Physiol 306(5): F496-504
    › Primary publication · 24370591 (PubMed) · PMC3949031 (PubMed Central)
  20. Abnormal trafficking of endogenously expressed BMPR2 mutant allelic products in patients with heritable pulmonary arterial hypertension. Frump AL, Lowery JW, Hamid R, Austin ED, de Caestecker M (2013) PLoS One 8(11): e80319
    › Primary publication · 24224048 (PubMed) · PMC3818254 (PubMed Central)
  21. Aberrant activation, nuclear localization, and phosphorylation of Yes-associated protein-1 in the embryonic kidney and Wilms tumor. Murphy AJ, Pierce J, de Caestecker C, Libes J, Neblett D, de Caestecker M, Perantoni AO, Tanigawa S, Anderson JR, Dome JS, Das A, Carroll TJ, Lovvorn HN (2014) Pediatr Blood Cancer 61(2): 198-205
    › Primary publication · 24115727 (PubMed) · PMC3955491 (PubMed Central)
  22. Kidney regeneration: common themes from the embryo to the adult. Cirio MC, de Groh ED, de Caestecker MP, Davidson AJ, Hukriede NA (2014) Pediatr Nephrol 29(4): 553-64
    › Primary publication · 24005792 (PubMed) · PMC3944192 (PubMed Central)
  23. Ischemia-reperfusion model of acute kidney injury and post injury fibrosis in mice. Skrypnyk NI, Harris RC, de Caestecker MP (2013) J Vis Exp (78)
    › Primary publication · 23963468 (PubMed) · PMC3854859 (PubMed Central)
  24. Histone deacetylase inhibitor enhances recovery after AKI. Cianciolo Cosentino C, Skrypnyk NI, Brilli LL, Chiba T, Novitskaya T, Woods C, West J, Korotchenko VN, McDermott L, Day BW, Davidson AJ, Harris RC, de Caestecker MP, Hukriede NA (2013) J Am Soc Nephrol 24(6): 943-53
    › Primary publication · 23620402 (PubMed) · PMC3665399 (PubMed Central)
  25. Deletion of fibroblast growth factor receptor 2 from the peri-wolffian duct stroma leads to ureteric induction abnormalities and vesicoureteral reflux. Walker KA, Sims-Lucas S, Di Giovanni VE, Schaefer C, Sunseri WM, Novitskaya T, de Caestecker MP, Chen F, Bates CM (2013) PLoS One 8(2): e56062
    › Primary publication · 23409123 (PubMed) · PMC3567073 (PubMed Central)
  26. CITED1 expression in liver development and hepatoblastoma. Murphy AJ, de Caestecker C, Pierce J, Boyle SC, Ayers GD, Zhao Z, Libes JM, Correa H, Walter T, Huppert SS, Perantoni AO, de Caestecker MP, Lovvorn HN (2012) Neoplasia 14(12): 1153-63
    › Primary publication · 23308048 (PubMed) · PMC3540941 (PubMed Central)
  27. HDAC inhibitors in kidney development and disease. Brilli LL, Swanhart LM, de Caestecker MP, Hukriede NA (2013) Pediatr Nephrol 28(10): 1909-21
    › Primary publication · 23052657 (PubMed) · PMC3751322 (PubMed Central)
  28. SIX2 and CITED1, markers of nephronic progenitor self-renewal, remain active in primitive elements of Wilms' tumor. Murphy AJ, Pierce J, de Caestecker C, Taylor C, Anderson JR, Perantoni AO, de Caestecker MP, Lovvorn HN (2012) J Pediatr Surg 47(6): 1239-49
    › Primary publication · 22703800 (PubMed) · PMC3377935 (PubMed Central)
  29. Ischemia-reperfusion injury of the mouse kidney. Oxburgh L, de Caestecker MP (2012) Methods Mol Biol : 363-79
    › Primary publication · 22639277 (PubMed)
  30. Molecular characterization of Wilms' tumor from a resource-constrained region of sub-Saharan Africa. Murphy AJ, Axt JR, de Caestecker C, Pierce J, Correa H, Seeley EH, Caprioli RM, Newton MW, de Caestecker MP, Lovvorn HN (2012) Int J Cancer 131(6): E983-94
    › Primary publication · 22437966 (PubMed) · PMC3402639 (PubMed Central)
  31. FGF/EGF signaling regulates the renewal of early nephron progenitors during embryonic development. Brown AC, Adams D, de Caestecker M, Yang X, Friesel R, Oxburgh L (2011) Development 138(23): 5099-112
    › Primary publication · 22031548 (PubMed) · PMC3210493 (PubMed Central)
  32. Zebrafish kidney development: basic science to translational research. Swanhart LM, Cosentino CC, Diep CQ, Davidson AJ, de Caestecker M, Hukriede NA (2011) Birth Defects Res C Embryo Today 93(2): 141-56
    › Primary publication · 21671354 (PubMed) · PMC3694221 (PubMed Central)
  33. Organ-specific defects in insulin-like growth factor and insulin receptor signaling in late gestational asymmetric intrauterine growth restriction in Cited1 mutant mice. Novitskaya T, Baserga M, de Caestecker MP (2011) Endocrinology 152(6): 2503-16
    › Primary publication · 21486933 (PubMed) · PMC3100618 (PubMed Central)
  34. ID family protein expression and regulation in hypoxic pulmonary hypertension. Lowery JW, Frump AL, Anderson L, DiCarlo GE, Jones MT, de Caestecker MP (2010) Am J Physiol Regul Integr Comp Physiol 299(6): R1463-77
    › Citation · 20881097 (PubMed) · PMC3007180 (PubMed Central)
  35. Bmp2 and Bmp4 exert opposing effects in hypoxic pulmonary hypertension. Anderson L, Lowery JW, Frank DB, Novitskaya T, Jones M, Mortlock DP, Chandler RL, de Caestecker MP (2010) Am J Physiol Regul Integr Comp Physiol 298(3): R833-42
    › Citation · 20042692 (PubMed) · PMC2838658 (PubMed Central)
  36. Placental insufficiency associated with loss of Cited1 causes renal medullary dysplasia. Sparrow DB, Boyle SC, Sams RS, Mazuruk B, Zhang L, Moeckel GW, Dunwoodie SL, de Caestecker MP (2009) J Am Soc Nephrol 20(4): 777-86
    › Citation · 19297558 (PubMed) · PMC2663829 (PubMed Central)
  37. Fate mapping using Cited1-CreERT2 mice demonstrates that the cap mesenchyme contains self-renewing progenitor cells and gives rise exclusively to nephronic epithelia. Boyle S, Misfeldt A, Chandler KJ, Deal KK, Southard-Smith EM, Mortlock DP, Baldwin HS, de Caestecker M (2008) Dev Biol 313(1): 234-45
    › Citation · 18061157 (PubMed) · PMC2699557 (PubMed Central)
  38. Increased susceptibility to hypoxic pulmonary hypertension in Bmpr2 mutant mice is associated with endothelial dysfunction in the pulmonary vasculature. Frank DB, Lowery J, Anderson L, Brink M, Reese J, de Caestecker M (2008) Am J Physiol Lung Cell Mol Physiol 294(1): L98-109
    › Citation · 18024717 (PubMed)
  39. Cited1 and Cited2 are differentially expressed in the developing kidney but are not required for nephrogenesis. Boyle S, Shioda T, Perantoni AO, de Caestecker M (2007) Dev Dyn 236(8): 2321-30
    › Citation · 17615577 (PubMed)
  40. Bone morphogenetic protein 4 promotes vascular remodeling in hypoxic pulmonary hypertension. Frank D, Johnson J, de Caestecker M (2005) Chest 128(6 Suppl): 590S-591S
    › Primary publication · 16373851 (PubMed)
  41. Bone morphogenetic protein 4 promotes pulmonary vascular remodeling in hypoxic pulmonary hypertension. Frank DB, Abtahi A, Yamaguchi DJ, Manning S, Shyr Y, Pozzi A, Baldwin HS, Johnson JE, de Caestecker MP (2005) Circ Res 97(5): 496-504
    › Citation · 16100039 (PubMed)
  42. Cited1 is a bifunctional transcriptional cofactor that regulates early nephronic patterning. Plisov S, Tsang M, Shi G, Boyle S, Yoshino K, Dunwoodie SL, Dawid IB, Shioda T, Perantoni AO, de Caestecker MP (2005) J Am Soc Nephrol 16(6): 1632-44
    › Citation · 15843474 (PubMed)